首页> 美国政府科技报告 >TNK2 Tyrosine Kinase as a Novel Therapeutic Target in Triple-Negative Breast Cancer.

【24h】

TNK2 Tyrosine Kinase as a Novel Therapeutic Target in Triple-Negative Breast Cancer.

机译：TNK2酪氨酸激酶作为三阴性乳腺癌的新型治疗靶点。

获取原文

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Pandey, A.;
展开▼
作者单位

展开▼
年度 2017
页码 1-13
总页数 13
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET [J] . Shen Yingying, Zhang Wei, Liu Jianghua, International Journal of Cancer =: Journal International du Cancer . 2019,第3期

机译：DCC-2036的治疗活性是一种新型酪氨酸激酶抑制剂，通过靶向AXL / MET对抗三阴性乳腺癌患者衍生的异种移植物
2. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE [J] . Suthe Sreedhar Reddy, Yao Hang-Ping, Weng Tian-Hao, Molecular cancer therapeutics . 2018,第12期

机译：Ron受体酪氨酸激酶作为消除三阴性乳腺癌的治疗靶标：抗RON ADC ZT / G4-MMAE的功效
3. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. [J] . Corkery B, Crown J, Clynes M Annals of oncology: official journal of the European Society for Medical Oncology . 2009,第5期

机译：表皮生长因子受体作为三阴性乳腺癌的潜在治疗靶标。
4. Profiling and Cross-Talk of Tyrosine Phosphorylation with Lysine Acetylation and Succinylation in Tyrosine Kinase Inhibitor Resistant Breast Cancer Cells [C] . Hongbo Gu, Erik J. Soderblom, J. Will Thompson, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：酪氨酸激酶抑制剂抗性乳腺癌细胞赖氨酸乙酰化和琥珀酸抗蛋白酶磷酸化的分析和串扰
5. An RNAi screen targeting the protein tyrosine kinases identifies Bruton's tyrosine kinase (BTK) as a breast cancer cell survival factor. [D] . Eifert, Cheryl. 2009

机译：靶向蛋白质酪氨酸激酶的RNAi筛选可将布鲁顿酪氨酸激酶（BTK）识别为乳腺癌细胞生存因子。
6. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer [O] . Xinyan Wu, Muhammad Zahari Saddiq, Santosh Renuse, 2017

机译：非受体酪氨酸激酶TNK2 / ACK1是三阴性乳腺癌的新型治疗靶点
7. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. [O] . Sara Jansson, Pär-Ola Bendahl, Dorthe Aamand Grabau, 2014

机译：在4q12处紧密间隔的三种受体酪氨酸激酶c-KIT，VEGFR2和pDGFRα在三阴性乳腺癌中显示增加的蛋白质表达。

TNK2 Tyrosine Kinase as a Novel Therapeutic Target in Triple-Negative Breast Cancer.

著录项

引文网络

相似文献

相关主题

期刊订阅